Petra Steinacker

List of Publications by Year
in descending order

57 papers	3,002 citations	172457 29 h-index	168389 53 g-index
58 all docs	58 docs citations	58 times ranked	3863 citing authors

#	Article	IF	Citations
1	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	1.9	39
2	Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. Journal of Neural Transmission, 2022, 129, 207-230.	2.8	26
3	Blood β-Synuclein and Neurofilament Light Chain During the Course of Prion Disease. Neurology, 2022, , 10.1212/WNL.0000000000200002.	1.1	11
4	Serum <scp>Beta-Synuclein</scp> Is Higher in Down Syndrome and Precedes Rise of <scp>pTau181</scp>. Annals of Neurology, 2022, 92, 6-10.	5.3	9
5	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	1.9	21
6	Cerebrospinal Fluid Levels of Prodynorphin-Derived Peptides are Decreased in Huntington's Disease. Movement Disorders, 2021, 36, 492-497.	3.9	12
7	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.7	14
8	Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 330.	2.7	12
9	Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Translational Neurodegeneration, 2021, 10, 31.	8.0	18
10	Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. Journal of Psychiatric Research, 2021, 144, 54-58.	3.1	34
11	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 349-356.	1.9	31
12	Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. Journal of Neurology, 2020, 267, 36-44.	3.6	47
13	CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer's Research and Therapy, 2020, 12, 2.	6.2	86
14	Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. World Journal of Biological Psychiatry, 2020, 21, 148-154.	2.6	18
15	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.7	15
16	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with <i>C9orf72</i> hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	1.9	33
17	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	3.7	43
18	CSF SerpinA1 in Creutzfeldt-Jakob disease and frontotemporal lobar degeneration. Annals of Clinical and Translational Neurology, 2020, 7, 191-199.	3.7	16

#	Article	IF	Citations
19	S-ketamine induces acute changes in the proteome of the mouse amygdala. Journal of Proteomics, 2020, 216, 103679.	2.4	6
20	CSF Ubiquitin Levels Are Higher in Alzheimer's Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease. Biomolecules, 2020, 10, 497.	4.0	8
21	Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. Translational Psychiatry, 2020, 10, 144.	4.8	20
22	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	2.6	171
23	Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984605.	3.5	41
24	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	3.1	81
25	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	1.9	96
26	Biomarkers for diseases with TDP-43 pathology. Molecular and Cellular Neurosciences, 2019, 97, 43-59.	2.2	38
27	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	1.9	174
28	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 21-22.	3.1	6
29	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.1	148
30	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
31	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.1	85
32	Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid. Journal of Proteome Research, 2018, 17, 516-523.	3.7	23
33	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.1	73
34	Poly‹scp›GP‹/scp› in cerebrospinal fluid links ‹i›C9orf72‹/i›â€‘associated dipeptide repeat expression to the asymptomatic phase of ‹scp›ALS‹/scp›/‹scp›FTD‹/scp›. EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90
35	Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Expert Review of Proteomics, 2017, 14, 499-514.	3.0	26
36	Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Review of Proteomics, 2017, 14, 769-777.	3.0	27

#	Article	IF	Citations
37	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.7	63
38	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311387.	1.9	207
39	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	3.3	24
40	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737.	3.3	81
41	Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis. Journal of Neurology, 2016, 263, 954-960.	3.6	13
42	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.7	84
43	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Molecular and Cellular Proteomics, 2016, 15, 3126-3138.	3.8	92
44	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of Neurology, 2016, 79, 152-158.	5.3	188
45	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. Movement Disorders, 2016, 31, 848-860.	3.9	52
46	Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. Journal of Neurochemistry, 2016, 138, 184-192.	3.9	26
47	Aggregated α-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2016, 186, 2152-2161.	3.8	17
48	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. Journal of Neural Transmission, 2016, 123, 289-296.	2.8	26
49	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 757-768.	2.3	21
50	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobärdegeneration. Laboratoriums Medizin, 2012, 36, .	0.6	1
51	14-3-3 proteins in neurodegeneration. Seminars in Cell and Developmental Biology, 2011, 22, 696-704.	5.0	85
52	Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis. PLoS ONE, 2011, 6, e23600.	2.5	36
53	ERK2 is Increased in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients. Journal of Alzheimer's Disease, 2010, 22, 119-128.	2.6	9
54	Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt–Jakob disease. Proteomics, 2010, 10, 81-89.	2.2	39

#	Article	IF	Citations
55	Neuroprotective Function of Cellular Prion Protein in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2010, 176, 1409-1420.	3.8	37
56	Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Journal of Neural Transmission, 2009, 116, 1169-1178.	2.8	26
57	TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 1481.	4.5	186